- Led platform chemistry in the identification of chemical matter for over 10 deubiquitinases - Chemistry lead for flagship rare disease program leading to proof-of-concept by improved efficacy over standard of care as well as stabilisation of pharmacoresistant mutants - Helped design and triage over 20 high throughput screens using DEL, ASMS and MST - Informed evolution of screening strategy to rapidly and selectively identify silent binders - Designed heterobifunctionals balancing aggressive timelines to proof-of-concept while maintaining favourable physiochemical properties for developability - Developed a diverse set of linkers to efficiently explore bifunctionals with a higher success rate - Directed and managed over 50 chemists across multiple CROs in Europe and Asia - Guided a direct report through on-boarding and goal setting and mentored him through his first lead chemist role

- Advanced hit-to-lead compounds with a focus on a known selectivity issue while maintaining stability, permeability and potency from the earliest stages - Triaged and advanced hits from biochemical high-throughput screening and DNA Encoded Libraries, through truncation and identification of minimum pharmacophore - Coordinated routine assay submissions between chemists, compound management and biochemistry including compound selection and QC - Communicated progress and goals within and across departments and up to leadership team - Created and presented project-specific introduction to medicinal chemistry seminar for collaborating biochemists and biologists - Provided training, guidance and mentorship for lab members in target design and med. chem. synthesis

- Contributing to multiple projects targeting pathways in metabolism and DNA damage repair through the development of small molecule therapeutics- Triaged hits from multiple HTS against several targets through counter screening, PAINS and assessment of drug-like properties- Led the optimisation of scaffolds from micromolar HTS hit to sub nanomolar potency while focusing on stability, selectivity and drug-like properties including directing CRO resources- Experienced working with multiple CROs across organic synthesis, biochemistry and DMPK- Proposed and established interdisciplinary 'Lunch and Learn' sessions throughout the company covering topics ranging from IP protection to toxicology

Total synthesis of vinblastine and heterocycle analogues via a common late-stage intermediateOutline: Formal total synthesis of vinblastine via a key intermediate and subsequent divergent heterocycle introduction to generate a series of analogues bearing deep seated structural variation. Generation of a series of biologically active molecules to counter multi-drug resistance utilising a wide range of classical and modern organic synthesis techniques.

Targeting the Nrf2/Keap1 InteractionOutline: Design and synthesis of a series of cell penetrating peptides to upregulate the innate antioxidant response via disruption of a key protein-protein interaction, followed by optimisation of sequence and structure to improve both potency and stability. In addition, usage of cell culture techniques to assess increased mRNA transcription and protein production as well as development of fluorescence based assays.

Phospha-Oseltamivir - New Prodrug Concepts and Conjugation ApproachesOutline: Synthesis of a Phospha-Oseltamivir prodrug to improve bioavailability and allow further scope for functionalisation. In addition, work towards synthesis of a linker for the immobilisation of Phospha-Oseltamivir on gold nanoparticles.